Status: Recruiting
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.
Participants needed: 180
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Shandong Suncadia Medicine Co., Ltd.Updated: Apr 3, 2026Locations: 2
Eligibility criteria
Female, aged 18-75 (inclusive); [+5]
Within 5 years prior to the first dose of study medication, the occurrence of ot... [+16]